Filtered By:
Condition: Heart Attack
Countries: USA Health
This page shows you your search results in order of date. This is page number 9.
Order by Relevance | Date
Total 340 results found since Jan 2013.
Insights Into Platelet-Derived MicroRNAs in Cardiovascular and Oncologic Diseases: Potential Predictor and Therapeutic Target
Front Cardiovasc Med. 2022 Jun 9;9:879351. doi: 10.3389/fcvm.2022.879351. eCollection 2022.ABSTRACTNon-communicable diseases (NCDs), represented by cardiovascular diseases and cancer, have been the leading cause of death globally. Improvements in mortality from cardiovascular (CV) diseases (decrease of 14%/100,000, United States) or cancers (increase 7.5%/100,000, United States) seem unsatisfactory during the past two decades, and so the search for innovative and accurate biomarkers of early diagnosis and prevention, and novel treatment strategies is a valuable clinical and economic endeavor. Both tumors and cardiovascular...
Source: Atherosclerosis - June 27, 2022 Category: Cardiology Authors: Qianru Leng Jie Ding Meiyan Dai Lei Liu Qing Fang Dao Wen Wang Lujin Wu Yan Wang Source Type: research
New Data From Two Large Studies Reinforce Effectiveness of Dual Pathway Inhibition (DPI) with XARELTO ® (rivaroxaban) Plus Aspirin in Patients with Coronary Artery Disease (CAD) and/or Peripheral Artery Disease (PAD)
RARITAN, N.J., May 23, 2022 – Findings from the XARELTO® (rivaroxaban) Phase 3 COMPASS Long-Term Open Label Extension (LTOLE) study and the XARELTO® in Combination with Acetylsalicylic Acid (XATOA) registry have been published in the European Society of Cardiology’s (ESC) European Heart Journal, Cardiovascular Pharmacotherapy. Additionally, the XATOA registry was presented at the American Congress of Cardiology’s 71st Annual Scientific Session (ACC.22). These studies provide further evidence supporting the role of dual pathway inhibition (DPI) with the XARELTO® vascular dose (2.5 mg twice daily plus aspirin 100 mg...
Source: Johnson and Johnson - May 23, 2022 Category: Pharmaceuticals Source Type: news
Medicare Bundled Payment Policy on Anemia Care, Major Adverse Cardiovascular Events, and Mortality among Adults Undergoing Hemodialysis
CONCLUSIONS: The Medicare reimbursement policy and Food and Drug Administration-recommended erythropoietin-stimulating agent dosing changes were associated with lower erythropoietin-stimulating agent use and lower hemoglobin levels. These changes in anemia care were associated with lower risks of major adverse cardiovascular event, stroke, mortality, and heart failure but higher risk of acute myocardial infarction among adults receiving hemodialysis.PMID:35589388 | DOI:10.2215/CJN.14361121
Source: Clinical Journal of the American Society of Nephrology : CJASN - May 19, 2022 Category: Urology & Nephrology Authors: Haesuk Park Raj Desai Xinyue Liu Steven M Smith Juan Hincapie-Castillo Linda Henry Amie Goodin Saraswathi Gopal Carl J Pepine Raj Mohandas Source Type: research
Use of Prescription Medications With Cardiovascular Adverse Effects Among Older Adults in the United States
CONCLUSIONS AND RELEVANCE: In this community-based cohort of older adults with no prior cardiovascular disease, the use of MACE medications was independently and consistently associated with an increased risk of such events in a dose-response fashion. This article is protected by copyright. All rights reserved.PMID:35569118 | DOI:10.1002/pds.5477
Source: Atherosclerosis - May 15, 2022 Category: Cardiology Authors: Katharine Ozenberger G Caleb Alexander Jung-Im Shin Eric A Whitsel Dima M Qato Source Type: research
Hypertensive Disorders in Pregnancy and Mortality at Delivery Hospitalization - United States, 2017-2019
MMWR Morb Mortal Wkly Rep. 2022 Apr 29;71(17):585-591. doi: 10.15585/mmwr.mm7117a1.ABSTRACTHypertensive disorders in pregnancy (HDPs), defined as prepregnancy (chronic) or pregnancy-associated hypertension, are common pregnancy complications in the United States.* HDPs are strongly associated with severe maternal complications, such as heart attack and stroke (1), and are a leading cause of pregnancy-related death in the United States.† CDC analyzed nationally representative data from the National Inpatient Sample to calculate the annual prevalence of HDP among delivery hospitalizations and by maternal characteristics, a...
Source: MMWR Morb Mortal Wkl... - April 28, 2022 Category: Epidemiology Authors: Nicole D Ford Shanna Cox Jean Y Ko Lijing Ouyang Lisa Romero Tiffany Colarusso Cynthia D Ferre Charlan D Kroelinger Donald K Hayes Wanda D Barfield Source Type: research
One-Year Outcomes After Transcarotid Artery Revascularization (TCAR) in the ROADSTER 2 TRIAL
CONCLUSIONS: In patients with high risk factors, TCAR yields high technical success with a low stroke and death rate at one year. Further comparative studies to CEA are warranted.PMID:35381327 | DOI:10.1016/j.jvs.2022.03.872
Source: Atherosclerosis - April 5, 2022 Category: Cardiology Authors: Vikram S Kashyap Kristine L So Peter A Schneider Rama Rathore Thi Pham Raghu L Motaganahalli Douglas W Massop Mazin I Foteh Hans-Henning Eckstein Jeffrey Jim Jose Ignacio Leal Lorenzo James G Melton Source Type: research
New ERLEADA ® (apalutamide) Analysis Demonstrates Rapid, Deep Prostate-Specific Antigen (PSA) Response in Patients with Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
SAN FRANCISCO, Feb. 14, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new real-world evidence data showing the initiation of ERLEADA® (apalutamide) results in high rates of rapid and deep prostate-specific antigen (PSA) response among patients with metastatic castration-sensitive prostate cancer (mCSPC). In a separate post-hoc analysis of the registrational Phase 3 SPARTAN and TITAN studies, rapid and deep PSA responses with ERLEADA® were associated with improvement in patient-reported outcomes (PROs) related to quality of life, physical wellbeing, pain, and fatigue intensity. The...
Source: Johnson and Johnson - February 14, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Evaluating community-driven cardiovascular health policy changes in the United States using agent-based modeling
This study used an agent-based model to estimate long-term impacts of a comprehensive smoke-free policy, as it was implemented in two communities, Arlington and Mesquite, Texas. The model predicted the percentage of myocardial infarction (MI), stroke, and diabetes in the population 10 and 20 years following policy adoption. In Arlington, the percentage of the population with these conditions each decreased by approximately 0.5% over 20 years; in Mesquite, the percentage of the population with diabetes, myocardial infarction (MI), and stroke decreased by 1.1%, 0.6%, and 0.3%, respecti vely, after 20 years. The results w...
Source: Journal of Public Health Policy - February 10, 2022 Category: Health Management Source Type: research
